Concizumab
Concizumab targets tissue factor pathway inhibitor and is used in the management of hemophilia. Associated biomarker assessments may support patient selection and treatment monitoring in bleeding disorders.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where Concizumab is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors Other · Blood |
|
Approvals defined at the solid tumor level where Concizumab is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report Concizumab as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports Concizumab as part of its biomarker panel.